ANI Pharmaceuticals (NASDAQ:ANIP) Announces Quarterly Earnings Results, Beats Expectations By $0.17 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) posted its earnings results on Friday. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17, FiscalAI reports. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same period in the previous year, the business posted $1.80 EPS. ANI Pharmaceuticals’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI reported record second-quarter revenue of $266 million, up 26% year over year, with adjusted EBITDA up 32% to a record $71.6 million and operating cash flow of $56.7 million.
• The company modestly lowered 2026 Cortrophin Gel revenue guidance to $520 million-$540 million, citing first-half performance, although it maintained expectations for strong second-half growth and reaffirmed total revenue guidance of $1.08 billion-$1.14 billion.
• Cortrophin revenue rose 43% year over year to $117.1 million, while the gout-focused sales-force expansion is showing encouraging early indicators: more than 95% of new representatives generated multiple cases and over one-third of prescribers initiated at least two cases.
• Generics revenue increased 10% to $99.1 million, with 12 products launched year to date and at least 15 expected for 2026; management also highlighted that approximately 95% of revenue comes from products manufactured in the U.S.
• ILUVIEN revenue declined 16% year over year to $18.7 million, primarily due to international shipment timing, though management reaffirmed its full-year guidance and expects more detailed uveitis trial data in the fourth quarter.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded down $4.38 during mid-day trading on Friday, reaching $78.25. 1,020,050 shares of the company traded hands, compared to its average volume of 293,035. ANI Pharmaceuticals has a fifty-two week low of $70.15 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The firm has a market cap of $1.78 billion, a PE ratio of 19.81 and a beta of 0.44. The stock has a fifty day simple moving average of $81.02 and a 200-day simple moving average of $79.37.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

Insider Transactions at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Monday, July 13th. The stock was sold at an average price of $81.84, for a total transaction of $40,920.00. Following the transaction, the vice president directly owned 77,390 shares in the company, valued at approximately $6,333,597.60. This trade represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the sale, the director directly owned 38,432 shares in the company, valued at $3,098,772.16. This represents a 20.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 88,029 shares of company stock valued at $6,954,472 over the last three months. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter worth about $28,000. Kemnay Advisory Services Inc. bought a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $48,000. State of Wyoming bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $50,000. Tower Research Capital LLC TRC grew its stake in shares of ANI Pharmaceuticals by 542.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock worth $113,000 after purchasing an additional 1,458 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its holdings in ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after buying an additional 134 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on ANIP. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim reaffirmed a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Finally, Canaccord Genuity Group initiated coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.